These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21850397)

  • 1. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
    Zeng X; Zhang H; Oh A; Zhang Y; Yee D
    Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
    Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
    Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
    Flanigan SA; Pitts TM; Eckhardt SG; Tentler JJ; Tan AC; Thorburn A; Leong S
    Clin Cancer Res; 2010 Nov; 16(22):5436-46. PubMed ID: 20943761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
    Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
    J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine.
    Khatri A; Brundage RC; Hull JM; Williams BW; Yee D; Kirstein MN
    AAPS J; 2012 Mar; 14(1):1-9. PubMed ID: 22101930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.
    Zeng X; Sachdev D; Zhang H; Gaillard-Kelly M; Yee D
    Clin Cancer Res; 2009 Apr; 15(8):2840-9. PubMed ID: 19351773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
    Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
    Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
    Fox EM; Miller TW; Balko JM; Kuba MG; Sánchez V; Smith RA; Liu S; González-Angulo AM; Mills GB; Ye F; Shyr Y; Manning HC; Buck E; Arteaga CL
    Cancer Res; 2011 Nov; 71(21):6773-84. PubMed ID: 21908557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
    Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
    Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
    Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
    Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
    J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
    Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
    BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor.
    Wu J; Li W; Craddock BP; Foreman KW; Mulvihill MJ; Ji QS; Miller WT; Hubbard SR
    EMBO J; 2008 Jul; 27(14):1985-94. PubMed ID: 18566589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
    Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
    Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
    Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
    Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
    [No Abstract]   [Full Text] [Related]  

  • 18. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
    Hou X; Huang F; Macedo LF; Harrington SC; Reeves KA; Greer A; Finckenstein FG; Brodie A; Gottardis MM; Carboni JM; Haluska P
    Cancer Res; 2011 Dec; 71(24):7597-607. PubMed ID: 22042792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds.
    Chan JY; Hackel BJ; Yee D
    Mol Cancer Ther; 2017 Jul; 16(7):1324-1334. PubMed ID: 28468775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
    Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
    PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.